TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Patients post allogeneic bone marrow transplant with watery diarrhea progressed on 2mg/kg of steroids after 3 days or failed to improve after 5 days.~* Patients may have skin or liver involvement with graft versus host disease.~* Patients should not have any infections etiology for diarrhea.~Exclusion criteria:~* None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- aGvHD (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Erector Spinae Plane Block for Postoperative Analgesia in Adult Patients Undergoing Thoracoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for thoracoscopy~* physical status I-III~Exclusion Criteria:~* allergy to local anaesthetics~* other contraindications to peripheral nerve blocks~* patients suffering from chronic pain condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erector spinae plane block (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Probiotics in the Prevention of Antibiotic Induced Diarrhea and Clostridium Difficile Associated Diarrhea.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients hospitalized on antibiotics (single or multiple; oral or IV) assuming that they are able to eat/drink so that they can take the pills.~* Regimen started within 48 hours of first course of antibiotics.~* Able to sign a consent form.~Exclusion Criteria:~diarrhea on admission; bowel pathology that could result in diarrhea (eg. IBD), bowel surgeries and pouches; immunocompromised state (including febrile aplasia, immunosuppressive therapy, ICU patients, HIV-positive patients and renal transplant patients); prosthetic heart valves or history of endocarditis and rheumatic heart disease; use of metronidazole, vancomycin or fidaxomycin prior to stool culture for Clostridium difficile toxins.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Probiotic-receiving group (Type: ACTIVE_COMPARATOR): The probiotic-receiving group will receive once daily probiotics containing 25Bn CFU of which: 5Bn CFU Lactobacillus rhamnosus GG, 5Bn CFU Sacchromyces boulardii, 5Bn CFU Bifidobacterium breve, 4.5Bn CFU Bifidobacterium lactis, 2.5 Bn CFU Lactobacillus acidophilus, 2.5Bn CFU Lactobacillus plantarum and 500Mn CFU Lactobacillus reuteri.
- Placebo (Type: PLACEBO_COMPARATOR): The placebo group will receive once daily, identical capsules containing 0 Bn CFU.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Postplacental Insertion of Levonorgestrel-releasing Intrauterine System (LNG-IUS) After Cesarean vs. Interval Insertion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant at time of enrollment~* Planning to undergo a scheduled cesarean delivery~* Desires to use the LNG-IUS for contraception~* Willing and able to sign an informed consent in English~* Willing to comply with the study protocol~* Age greater than or equal to 18 years~* English speaking~Exclusion Criteria:~* Allergy to either polyethylene or levonorgestrel, or other contraindications to use of the LNG-IUS~* Positive testing for Gonorrhea, Chlamydia, or trichomoniasis during the pregnancy without treatment and a subsequent test of cure confirming a negative result~* Presence of leiomyomata significantly distorting the uterine cavity and thus not allowing placement of the LNG-IUS~* Uterine anomaly which would not allow placement of the LNG-IUS~* Current cervical cancer or carcinoma in-situ~* Desire for repeat pregnancy in less than 12 months~* History of postabortal or postpartum sepsis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- postplacental insertion after cesarean (Type: EXPERIMENTAL): Immediate postplacental insertion of the LNG-IUS through the uterine incision during cesarean, within 10 minutes after delivery of the placenta~Device of intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
- delayed insertion group (Type: ACTIVE_COMPARATOR): Insertion of the LNG-IUS 4-8 weeks after cesarean delivery~Device of intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Analysis of Filmed Sequences for the Assessment of Discomfort in Atopic Dermatitis of Infants Under 6 Months of Age

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Atopic dermatitis patients :~Inclusion Criteria:~* Young infant Under 6 month~* Patient with AD (SCORAD between 25 and 50 for moderate AD and \> 50 for severe AD)~* Informed consent of the patient's parents~Healthy patients :~Inclusion Criteria:~* Young infant under 6 month~* Free of any pathology~* Informed consent of the patient's parents~Exclusion Criteria (for every patients) :~* Acute intercurrent disease~* Severe malformation~* Underage parents or parent unable to give their consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Months
- Healthy Volunteers: t

Study Arms:
- Atopic Dermatitis patients (Type: OTHER): Filmed consultation with a dermatologist. Laterality and tactile sensitivity test.
- Healthy patients (Type: OTHER): Filmed consultation with a dermatologist. Laterality and tactile sensitivity test.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Either gender greater than or equal to 18 years of age.~* Pancreatic cancer or cholangiocarcinoma unsuitable for surgical resection. Criteria of unresectability being based on 1) metastatic disease or 2) locally advanced.~* Biliary obstruction~* Blocked self expanding mesh metal stent (SEMS)~* Subjects capable of giving informed consent~* Life expectancy of at least 3 months~Exclusion Criteria:~* Cardiac Pacemaker~* Patient unstable for endoscopy~* Inability to give informed consent~* Uncorrected coagulopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiofrequency probe (ENDOHPB) (Type: EXPERIMENTAL): Intervention:~The EndoHPB is an endoscopic bipolar catheter designed to ablate tissue in malignant tumors within luminal structures, such as the biliary tree or pancreatic ducts. EndoHPB can be deployed via an ERCP or Percutaneous Transhepatic Cholangiographic (PTC) route. By using radiofrequency (RF) energy to heat the tissue in the duct prior to insertion of the stent, the surrounding tissue becomes coagulated and this may delay tumour growth and the time before the stent lumen becomes blocked. Thereby, allowing increased periods between the need for intervention and further stent deployment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Intermittent Oral-esophageal Tube Feeding in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 65 years.~* With the history of NPC and radiation therapy.~* With dysphagia occurred at least three years after radiotherapy (confirmed by videofluoroscopic swallowing study), in need of and feasible for enteral nutrition support.~* Conscious and with stable vital signs;~* Willing to participate and sign the written informed consent form either personally or by a family member.~Exclusion Criteria:~* Presence of other diseases that might cause dysphagia.~* With distant metastasis of tumors, or complicated with severe systemic disorders or malignancies.~* Concurrent participation in other treatments that could interfere with the trial.~* Inability to cooperate with treatment due to aphasia, mental health issues, etc.~* Received tube feeding for enteral nutrition support within the past three years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- The observation group (Type: EXPERIMENTAL): During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients\&#39; health condition. The observation group receives IOE for enteral nutrition support
- The control group (Type: ACTIVE_COMPARATOR): During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the patients\&#39; health condition.The control group receives NGT for enteral nutrition support

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Intraoperative Measuring of Small Bowel Length Compared to Measuring by Magnetic Resonance Imaging (MRI) in Morbid Obese Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* morbid obese patient~* scheduled for distal gastric bypass~* informed consent for operation and study obtained~Exclusion Criteria:~* history of former small bowel resection~* weight \> 150 kg~* history of claustrophobia~* general contraindications for MRI (pacer, joint prosthesis, ear implant, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Distal gastric bypass

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 14.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female subjects between ages of 18-65 years~* Body mass index of 18.0-35.0 kg/m2~* Non-smokers for at least 3 months~* Deemed healthy on the basis of a clinical history, physical examination, ECG, vital signs, and laboratory tests of blood and urine~* Agree to follow the contraception requirements of the trial~* Able to give fully informed written consent.~Exclusion Criteria:~* Positive tests for hepatitis B \& C, HIV~* Severe adverse reaction to any drug~* Drug or alcohol abuse~* Use of over-the-counter medication (with the exception of paracetamol \[acetaminophen\]) during the 7 days before the first dose of trial medication, or prescribed medication during the 28 days before first dose of trial medication~* Any vaccination within 4 weeks before dose of trial medication~* Participation in other clinical trials of unlicensed medicines within the previous 3 months~* Loss of more than 400 mL blood within the previous 3 months~* Vital signs outside the acceptable range~* Clinically relevant abnormal findings at the screening assessment~* Acute or chronic illness~* Clinically relevant abnormal medical history or concurrent medical condition~* Possibility that volunteer will not cooperate~* Females who are pregnant or lactating, or who are sexually active and not using a reliable method of contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- ensovibep dose 1 (infusion) (Type: EXPERIMENTAL): None
- ensovibep dose 2 (infusion) (Type: EXPERIMENTAL): None
- ensovibep dose 3 (infusion) (Type: EXPERIMENTAL): None
- placebo (infusion) (Type: PLACEBO_COMPARATOR): None
- ensovibep dose 4 (IV bolus) (Type: EXPERIMENTAL): None
- ensovibep dose 5 (IV bolus) (Type: EXPERIMENTAL): None
- ensovibep dose 6 (SC injection) (Type: EXPERIMENTAL): None
- ensovibep dose 7 (SC injection) (Type: EXPERIMENTAL): None
- ensovibep dose 8 (SC injection) (Type: EXPERIMENTAL): None
- ensovibep dose 9 (SC injection) (Type: EXPERIMENTAL): None
- ensovibep dose 10 (IM injection) (Type: EXPERIMENTAL): None
- ensovibep dose 11 (IM injection) (Type: EXPERIMENTAL): None
- ensovibep dose 12 (IM injection) (Type: EXPERIMENTAL): None
- ensovibep dose 13 (IM injection) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Prognostic Value of Human Papillomavirus (HPV) Detection in Cervical Intra-epithelial Neoplasia (CIN) Recurrence After Conization

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women over 18 years~* CIN 2 or 3 diagnosis at inclusion confirmed for a CIN3 diagnosis by conization.~* HPV detected by Hybrid Capture 2 or RLA genotyping.~* Informed and signed consent by the patient and the investigator~* Coverage by French social security~Exclusion Criteria:~* Pregnancy at the time of inclusion.~* Previous history conization.~* Atypical endometrial or glandular cells or evidence of carcinoma on conization.~* Previous vaccination with a prophylactic HPV vaccine.~* Active viral infections including HIV.~* Acquired or congenital immunodeficiency.~* Long term treatment by corticosteroids or immunosuppressive drugs.~* Persons under protection of law.~* Patients unable to meet the requirements of the protocol.~* Any condition that, according to the investigator, would prevent participation in the study or interfere with the objectives of the study (refusal of supervision at the University Hospital, expected change of address within 3 years, etc)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Women with CIN3 treated by conization (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Research Study on the Immunosuppressive Effects of a Cell Therapy Product on PBMC Isolated From Blood of Patients With Inflammatory Rheumatic Diseases

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects of 18 years of age or older~* Subjects must belong to one of this group: Rheumatoid Arthritis (RA) Subjects OR Psoriatic Arthritis (PsA) Subjects OR Spondylarthritis (SpA) Subjects~Exclusion Criteria:~* Subjects diagnosed with other autoimmune/inflammatory diseases other than Crohn's disease, psoriasis, uveitis, Sjögren's syndrome and auto-immune thyroiditis~* Subjects with an active cancer and currently receiving a cancer treatment~* Women with known pregnancy~* Breastfeeding women~* Subjects with a known history of HIV and/or Hepatitis B and/or Hepatitis C infection and/or positive for HBs antigens

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rheumatoid Arthritis (Type: None): Patients with Rheumatoid Arthritis
- Psoriatic Arthritis (Type: None): Patients with Psoriatic Arthritis
- Spondylarthritis (Type: None): Patients with Spondylarthritis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Proprioception Testing in Persons With Sensorimotor Impairment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Traumatic incomplete SCI, stroke or acquired brain injured ABI subjects.~* Able to tolerate sitting upright at for at least 1 hour.~* Significant, but not complete, motor deficit in the hand and wrist, as determined by the Study Physician performing the screening.~* Significant, but not complete somatosensory deficit in the hand and wrist as determined by the Study Physician performing the screening.~* Cognitively and behaviorally capable of complying with the regimen.~Exclusion Criteria:~* Fracture of the treated limb resulting in loss of range of motion.~* Progressive neurodegenerative disorder.~* DVT of the treated extremity.~* Uncontrolled seizure disorder.~* Uncontrolled high blood pressure/angina.~* Osteo- or rheumatoid arthritis limiting range of motion~* Contractures equal to or greater than 50% of the normal ROM.~* Chronic ITB therapy.~* Peripheral nerve injury of the treated extremity.~* Pain in affected limb or exercise intolerance.~* Participation in another therapy or activity-based program.~* Skin condition not tolerant of device.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AMES Therapy and Diagnostic (Type: EXPERIMENTAL): During treatment, the AMES device rotates the hand, into flexion and extension, while the patient assists with this motion,and while the lengthening muscle(s) are vibrated mechanically. At the end of the treatment, several diagnostic tests are performed to measure the participant's level of proprioceptive perception. This study provides for 25 AMES treatments and diagnostic tests over 8-13 weeks, at a rate of 2-3 sessions per week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Synaptic Plasticity and Cognitive Function in RASopathies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Group 1: NS, Group 2: NF1 (both genetically assured)~2. Age ≥16 years~3. The adolescent (≥16) and legal guardian who are capable to give their consent and understand the aim and rationale of the study. In case of doubts, an independent medical practitioner will evaluate the capacity to consent.~4. Signed informed consent if ≥ 16 years and legal guardian.~5. Persons who are ≥ 18 years old and capable to give their consent and understand the aim and rationale of the study. In case of doubts, an independent medical practitioner will evaluate the capacity to consent.~6. Signed informed consent if ≥ 18 years.~7. Male participants and female participants who are not capable of bearing children or who use a method of contraception that is medically approved by the health authority of the respective country.~Exclusion Criteria:~1. Epilepsy~2. Medication with known CNS effects~3. Severe mental retardation~4. Side effects during previous medication with and contraindications for LTG and/or LOV and/or TMS~5. Psychiatric diseases~6. Previous history of allergic reactions with LTG and LOV medications~7. Potentially unreliable patients~8. Patients who are not suitable for the study in the opinion of the investigator~9. Pregnancy (incl. positive urine pregnancy test)~10. Persons who are incapable of giving consent or do not understand the aim or rationale of the study.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Exp. I: Noonan Syndrome - Lovastatin (Type: EXPERIMENTAL): 200 mg Lovastatin daily for four days / Lovastatin-placebo (cross-over) prior to transcranial magnetic stimulation and test of attentional performance
- Exp. II: Noonan Syndrome - Lamotrigine (Type: EXPERIMENTAL): 300 mg Lamotrigine single dose / Lamotrigine-placebo prior to transcranial magnetic stimulation and test of attentional performance
- Exp. III: Neurofibromatosis Type 1 - Lamotrigine (Type: EXPERIMENTAL): 300 mg Lamotrigine single dose / Lamotrigine-placebo prior to transcranial magnetic stimulation and test of attentional performance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues